GSK Investigational Site

Liverpool, Merseyside L9 7AL

0 studies enrolling now · 14 studies all time

What they study most

Anaemia, Asthma, Atherosclerosis, Diabetes Mellitus, Type 2, HIV Infections, Influenza, Influenza, Human, Neoplasms, Prostate, Pulmonary Disease, Chronic Obstructive, Scleroderma, Systemic, Sepsis

Studies at this site

• A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically Suppressed — Completed
• Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND) — Completed
• Proof of Mechanism Study of GSK2330811 in Diffuse Cutaneous Systemic Sclerosis — Completed
• Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease — Completed
• SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma. — Completed
• Trial to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine GSK2186877A in Adults 65 Year of Age and Older — Completed
• GR270773 In The Treatment Of Suspected Or Confirmed Gram-Negative Severe Sepsis In Adults — Completed
• The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial — Completed
• ARI103094-Follow-Up Study for REDUCE Study Subjects — Completed
• Safety Study to Assess IV Zanamivir for Treatment of Influenza Infection in Patients Who Are in Hospital — Completed
• A Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine — Completed
• Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes — Completed
• "REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk — Completed
• Rosiglitazone on Microalbuminuria in Type 2 Diabetics — Completed